Andrew J. Schwab's Net Worth
Estimate Recalculated Jun 18, 2025 08:33PM EST
Who is Andrew J. Schwab
Andrew J. Schwab does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Enliven Therapeutics, Inc., Skye Bioscience, Inc., , Flexion Therapeutics Inc, Crinetics Pharmaceuticals, Inc., Entrada Therapeutics, Inc., Vor Biopharma Inc., Pear Therapeutics, Inc., IDEAYA Biosciences, Inc., Rallybio Corp, ARVINAS INC., 5:01 Acquisition Corp., IMPEL NEUROPHARMA INC, Cidara Therapeutics, Inc., VIVEVE MEDICAL, INC., scPharmaceuticals Inc., Cabaletta Bio, Inc., Akouos, Inc., Homology Medicines, Inc., Aprea Therapeutics, Inc., Audentes Therapeutics, Inc., PHASERX, INC., EPIRUS Biopharmaceuticals, Inc., and Artiva Biotherapeutics, Inc..
SEC CIK
Andrew J. Schwab's CIK is 0001598549
Past Insider Trading and Trends
2023 was Andrew J. Schwab's most active year for acquiring shares with 3 total transactions. Andrew J. Schwab's most active month to acquire stocks was the month of January. 2023 saw Andrew J. Schwab paying a total of $0.00 for 1,514,369 shares, this is the most they've acquired in one year.
No data available
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
